Hepatocellular Carcinoma Non-resectable Clinical Trials

73 clinical trials for Hepatocellular Carcinoma Non-resectable across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma — RECRUITING · PHASE2
• Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT — RECRUITING · PHASE2
• BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) — RECRUITING · NA
• Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma — RECRUITING · NA
• Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis — RECRUITING · PHASE2
• Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE2
• Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC — RECRUITING · PHASE2
• Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma — RECRUITING
• Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion — RECRUITING · PHASE2
• DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC — RECRUITING · PHASE2
• Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT — RECRUITING · PHASE3
• Y-90 SIRT for Unresectable HCC Larger Than 7cm — RECRUITING · PHASE2
• Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China — RECRUITING
• mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria — RECRUITING · PHASE2
• Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) — RECRUITING
• TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors — RECRUITING · NA
• Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC — RECRUITING · PHASE2
• Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC — RECRUITING · PHASE3
• Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC — RECRUITING · PHASE3
• Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC — RECRUITING · PHASE3
• A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and the treatment combination of Sorafenib plus 4SC-201 in patients with hepatocellular carcinoma exhibiting progressive disease under Sorafenib treatment — COMPLETED · PHASE2
• Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) — TERMINATED · PHASE2
• Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma — NOT_YET_RECRUITING · NA
• Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC — ACTIVE_NOT_RECRUITING · PHASE2
• Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) — ACTIVE_NOT_RECRUITING · NA
• A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma — NOT_YET_RECRUITING
• Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy — NOT_YET_RECRUITING · PHASE2
• The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma — COMPLETED · PHASE1
• SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC — COMPLETED
• Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene — TERMINATED · PHASE1
• Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment — COMPLETED · PHASE2
• A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE3
• Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC) — COMPLETED · NA
• Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) — NOT_YET_RECRUITING
• A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab — NOT_YET_RECRUITING · PHASE2
• Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab — OTHER · PHASE2
• Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma — OTHER
• Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT — COMPLETED
• Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. — OTHER · PHASE2
• A Study to Evaluate SHR-1210 in Subjects With Advanced HCC — COMPLETED · PHASE2
• Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT — COMPLETED
• Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma — OTHER · PHASE1
• Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus — OTHER · PHASE1
• TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT — OTHER · NA
• Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) — OTHER
• Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study — OTHER
• Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma — OTHER · NA

Refine this search